drugset / Trial / NCT00492466

Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies

NCT00492466

Phase 4 Completed 14 enrolled Biogen
NaSingle-groupOpen-labelTreatment

Summary

This study is to find out if Interferon-beta can recover its effectiveness in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta.

Timeline

Start
2003-03
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1a Protein / enzyme biologic 30 ug Intramuscular
Background Methylprednisolone Other / unclassified 500 mg Oral